GILD: EU Approves Trodelvy
GILD's Trodelvy approved by European Commission as first-line treatment for metastatic triple-negative breast cancer patients
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.